Omacor Data Inadequate To Support Use With Statins, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Added benefit was seen with simvastatin, but reviewers noted that statin doses in studies were too low. Labeling makes no mention of concomitant use with statins or other lipid-altering therapies. Reliant is pursuing additional indications for the omega-3 fatty acids product, including possible use with statins or its fenofibrate Antara.
You may also be interested in...
Reliant's Antara Launch Set For First Quarter, Omacor Will Be Later
The cholesterol products have the potential to transform the company by generating annual sales of $150 mil. each, CEO Ernest Mario says. Reliant is considering possible combinations for Omacor; options include Antara or a statin.
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).
No More NASHing Of Teeth: Madrigal’s Resmetirom Approval Ends Years Of Industry Frustration
US FDA clears first MASH (formerly NASH) therapy, nearly four years after one had been initially anticipated. With the accelerated approval path established, Madrigal gets the opportunity to create a marketplace with Rezdiffra (resmetirom), and candidates in the pipeline get a clear target.